静脉唑来膦酸治疗骨质疏松症的疗效：荟萃分析。

Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis.

机构信息

Department of Orthopaedics, the First Affiliated Hospital of Xinxiang Medical University, Weihui, PR China.

出版信息

Asian Pac J Trop Med. 2012 Sep;5(9):743-8. doi: 10.1016/S1995-7645(12)60118-7.

DOI:10.1016/S1995-7645(12)60118-7

PMID:22805729

Abstract

OBJECTIVE

To compare the effect of zoledronic acid in treatment and prevention of osteoporosis with placebo.

METHODS

Random control trials regarding zoledronic acid in treatment of osteoporosis were retrieved by selecting Medline, EMbase and Pubmed databases till April 2012. The RevMan software was used for all of the statistical analysis.

RESULTS

A total of 9 trials were included in this meta-analysis. The pooled effect showed that zoledronic acid could increase the bone mineral density by 2.98 times compared with placebo, and reduce the rate of fracture in patients by 32%. The results should the zoledronic acid intervention had significantly less serious adverse events than controls, and the odds ratio was 0.81 (0.76-0.87). The longer term intervention, more than 12 months intervention, could gain a better prevention effect for osteoporosis (OR, 95%CI for BMD was 3.35, 2.77-3.92; for fracture was 0.67, 0.54-0.82).

CONCLUSIONS

This present study shows that zoledronic acid could be effective approach in the prevention of osteoporosis, and could increase the bone mineral density and reduce the risk of fracture.

摘要

目的

比较唑来膦酸治疗和预防骨质疏松症的效果与安慰剂的差异。

方法

通过选择 Medline、EMbase 和 Pubmed 数据库，检索截至 2012 年 4 月关于唑来膦酸治疗骨质疏松症的随机对照试验。使用 RevMan 软件进行所有的统计分析。

结果

本荟萃分析共纳入 9 项试验。汇总效应表明，唑来膦酸可使骨密度比安慰剂增加 2.98 倍，使患者骨折率降低 32%。结果表明唑来膦酸干预的不良反应发生率明显低于对照组，比值比为 0.81（0.76-0.87）。长期干预（超过 12 个月）对骨质疏松症的预防效果更好（骨密度的 OR，95%CI 为 3.35，2.77-3.92；骨折的 OR 为 0.67，0.54-0.82）。